论文部分内容阅读
目的为进一步了解立其丁试验在诊断嗜铬细胞瘤中的阳性参考值和探讨行立其丁试验时监测血糖浓度在诊断嗜铬细胞瘤中的临床意义。方法选取术前行立其丁试验,术后病理确诊为嗜铬细胞瘤86例患者。根据立其丁试验结果分为3组:立其丁试验阳性、立其丁试验可疑、立其丁试验阴性,同时所有患者行立其丁试验时监测血糖浓度。结果86例嗜铬细胞瘤中立其丁试验阳性42例(占48.84%),可疑34例(占39.53%),阴性10例(占11.63%)。低血糖并立其丁试验阳性在诊断嗜铬细胞瘤中检出率最高,与非低血糖并立其丁试验阳性比较差异具有显著性(P<0.05);低血糖并立其丁试验可疑组比非低血糖并立其丁试验可疑组检出率亦高(P<0.05)。结论诊断嗜铬细胞瘤时立其丁试验阳性参考值应降低,可疑阳性者应高度怀疑为嗜铬细胞瘤;立其丁试验同时监测血糖浓度,更有助于早期诊断嗜铬细胞瘤。
Objective To further understand the positive reference value of Riegardin test in the diagnosis of pheochromocytoma and to explore the clinical significance of monitoring blood glucose concentration in the determination of pheochromocytoma when Rietibutatin test is performed. Methods Risidin test before surgery, postoperative pathology diagnosed as pheochromocytoma in 86 patients. According to the results of its establishment, the patients were divided into 3 groups: the drug was tested positive, the test was suspicious, the test was negative, and all patients were tested for glycemic control during their trial. Results Totally 42 cases (48.84%) were positive in pheochromocytoma neutrality test, 34 cases were suspicious (39.53%) and 10 cases were negative (11.63%). Hypoglycemic and erection test positive for pheochromocytoma in the diagnosis of the highest detection rate, and non-hypoglycemic and its standard test positive difference was significant (P <0.05); hypoglycemic and statin test suspicious group than non-low The detection rate of the blood sugar and the contractile test was also higher in the suspicious group (P <0.05). Conclusions The positive reference value for the determination of pethidine should be decreased when diagnosing pheochromocytoma. Suspicious positives should be highly suspected as pheochromocytoma. When the test is given, the blood glucose level should be monitored at the same time, which is more helpful for the early diagnosis of pheochromocytoma.